Effects of thrombin-derived C-terminal peptide on Candida
Infections due to the opportunistic fungus Candida have been on the rise the last decades, especially in immunocompromised individuals and in hospital settings. Unfortunately, the treatments available today are limited, especially because of their severe side effects in patients, increase of multi-drug resistance and the eukaryotic nature of Candida. Thrombin-derived C-terminal peptide 25 (TCP-25)
